“Which means a little variety of sufferers are treated with these substances each year when we await bigger research about security and efficacy,"suggests Abigail Calder, a copyright researcher and doctoral applicant for the University of Fribourg.Make sure to prioritize security, respect the substance, and embrace the transformative opportunity